Navigation Links
Tolerx Initiates Dosing of Otelixizumab, a Novel Type 1 Diabetes Agent, in DEFEND, a Phase 3 Clinical Trial
Date:8/6/2008

nts, which are not historical facts, constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Reform Act"). Statements regarding the outcomes sought to be realized in the Phase 3 clinical trial, the possibility that otelixizumab may have the potential to change type I diabetes treatment paradigms, the anticipated progress and development of otelixizumab, in type 1 diabetes and other disease indications, are all forward-looking statements. Such forward-looking statements involve risks, uncertainties and other factors that may cause the actual performance or achievements of Tolerx to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. Factors and risks that may impact management's expectations and affect the forward-looking statements shall include but not be limited to results of DEFEND and other future clinical studies, the ability to obtain regulatory approval for otelixizumab for type 1 diabetes or any other indication, the continuation of the collaboration with GSK, the introduction of competing therapies by other companies, and changes in the company's business plan or objectives. These statements reflect the view of Tolerx as of the date of this press release and should not be relied upon as reflecting the company's views at any date subsequent to this release. Tolerx undertakes no obligation to update or revise any forward-looking statements to reflect events or circumstances after the date of this press release.


'/>"/>
SOURCE Tolerx, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Tolerx Achieves Milestone with Completion of Phase Ib Clinical Study of TRX1 in Cutaneous Lupus Erythematosus
2. Tolerx Advancing Novel Type 1 Diabetes Agent into Phase III Clinical Trial Program Following End of Phase II FDA Meeting
3. Tolerx Announces Achievement of Milestones upon anti-CD4 Antibody Program Advancement and Initiation of Phase 1 Clinical Trial
4. Carrington Subsidiary DelSite Initiates Critical Toxicology Studies of Its Nasal Powder Bird Flu Vaccine
5. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
6. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
7. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
8. MedImmune Initiates Phase 2a Multi-Dose Study in Patients with Asthma
9. Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma
10. Nuvelo Re-Initiates SONOMA-3 Trial of Alfimeprase in Patients With Catheter Occlusion
11. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/7/2015)... , July 7, 2015 Noting the need ... pricing policies currently practiced by the rapidly consolidating pharmacy ... (SCPC) today praised Ohio Governor ... a new state effort to help pull back the ... "We applaud Governor Kasich for bringing badly-needed ...
(Date:7/7/2015)... , July 7, 2015 Biobanks ... Helping Your Influence  ,Are you interested ... so, now gain technological and commercial predictions from 2015. ... explore trends in research and development, results, opportunities and ... visiongain shows you what,s possible for biobanking and ...
(Date:7/7/2015)... , 7. Juli 2015 ... -Technik für klinische Studien, gab heute bekannt, dass ... führendes Unternehmen bei Gewinnung und Erhalt von Patienten ... Tochtergesellschaften MediciGlobal , Ltd. und Access to ... auch einen Dienst zum Auffinden von Patienten, die ...
Breaking Medicine Technology:National LTC Pharmacy Leader Praises Kasich Effort to Bring Transparency to PBM Drug Pricing 2National LTC Pharmacy Leader Praises Kasich Effort to Bring Transparency to PBM Drug Pricing 3Biobanking for Medicine: Technology, Industry and Market 2015-2025 2Biobanking for Medicine: Technology, Industry and Market 2015-2025 3Biobanking for Medicine: Technology, Industry and Market 2015-2025 4Biobanking for Medicine: Technology, Industry and Market 2015-2025 5Biobanking for Medicine: Technology, Industry and Market 2015-2025 6Biobanking for Medicine: Technology, Industry and Market 2015-2025 7Biobanking for Medicine: Technology, Industry and Market 2015-2025 8Biobanking for Medicine: Technology, Industry and Market 2015-2025 9Biobanking for Medicine: Technology, Industry and Market 2015-2025 10BioClinica übernimmt MediciGroup 2BioClinica übernimmt MediciGroup 3BioClinica übernimmt MediciGroup 4
... Held at 9:00 a.m. Eastern Time Today, May 26, ... (Nasdaq: UTHR ) announced today that the ... ADCIRCA(TM) (tadalafil) tablets for oral administration, with a recommended ... type 5 (PDE5) inhibitor for the treatment of pulmonary ...
... 23 Amid all the speculation over what course ... Replikins Ltd. ( www.replikins.com ) last week ... and determined that the infectivity of the H1N1 virus ... low for the immediate future.The company,s quantitative analysis of ...
Cached Medicine Technology:FDA Approves ADCIRCA(TM) (Tadalafil) Tablets for the Treatment of Pulmonary Arterial Hypertension 2FDA Approves ADCIRCA(TM) (Tadalafil) Tablets for the Treatment of Pulmonary Arterial Hypertension 3FDA Approves ADCIRCA(TM) (Tadalafil) Tablets for the Treatment of Pulmonary Arterial Hypertension 4Swine Flu (H1N1) Infectivity to Increase Markedly and Lethality to Remain Low According to Latest Replikin* Peptide Genomic Data 2
(Date:7/7/2015)... ... July 07, 2015 , ... ... Southwest, including Giant, Mustang, Sun Dial and Howdy’s, raised more than $524,286 ... 2015 fundraising goal by nearly $100,000, to help support children fighting muscular ...
(Date:7/7/2015)... ... July 07, 2015 , ... Difass USA, a modern supplement brand committed ... stressful days at work is knowing that there is hopefully a vacation to look ... free as imagined. Planning for a vacation can be quite stressful, and it’s difficult ...
(Date:7/7/2015)... ... July 07, 2015 , ... This week Northeast ... brand new website. The website’s goal is to provide patients with detailed information ... tools, including requesting appointments online. , Part of the center’s rebranding efforts, the ...
(Date:7/7/2015)... ... July 07, 2015 , ... ... Consulting announced today that the two firms have merged to form Camber ... health and biopharma sectors. The merger combines SwitchPoint’s strategy consulting expertise with ...
(Date:7/7/2015)... ... 2015 , ... Greatist today announced the acquisition of Blood, ... the most fun activities to do with friends. , The acquisition of BSC strengthens ... opportunity for events, e-commerce, and brand partnerships. , “I’ve been a huge fan of ...
Breaking Medicine News(10 mins):Health News:Western Refining Raises $524,286 to Help Send Kids with Neuromuscular Disease to MDA Summer Camp 2Health News:Western Refining Raises $524,286 to Help Send Kids with Neuromuscular Disease to MDA Summer Camp 3Health News:Difass USA Offers Eight Tips to Help Relax and Enjoy Summer Vacation 2Health News:Difass USA Offers Eight Tips to Help Relax and Enjoy Summer Vacation 3Health News:Northeast Nebraska Imaging Launches New Patient Friendly Website 2Health News:SwitchPoint and Hope Consulting Have Merged to Form Camber Collective 2Health News:Greatist Acquires Active Lifestyle Brand Blood, Sweat & Cheers 2
... 19 Studies have shown wearing a helmet while riding a ... yet every three days, a child in the United States is ... children are treated in emergency rooms due to bicycle-related head injuries. ... of Michigan C.S. Mott Children,s Hospital National Poll on Children,s ...
... in patients , FRIDAY, June 19 (HealthDay News) -- ... explain brain gray matter reductions experienced by patients with ... an association between fibromyalgia and reductions in gray matter, ... In this new study, Dr. Patrick B. Wood, of ...
... of E. coli infection in 28 states , ... warning consumers not to eat any Nestlé Toll House refrigerated ... coli contamination. , In response to the Food and ... voluntarily recalling its Toll House refrigerated cookie dough items. , ...
... 19 Warner Chilcott Limited (Nasdaq: WCRX ) ... Mid-Year Equity Conference on Wednesday, June 24, 2009 at 2:30 ... Fuhrmann, Senior Director, Investor Relations. , , Warner Chilcott,s ... www.wcrx.com under the Investor Relations tab. An ...
... , Brio Active opens its doors this month, offering a ... its core. , , DENVER, June 19 Brio ... vibration, a relatively new fitness concept in the U.S., with ... strength, flexibility, balance, energy, bone density, and neuromuscular coordination. ...
... ... ... - Last week, the World Health Organization declared the H1N1 virus, also commonly referred to ... urging healthcare providers to take precautions to limit the spread of the virus from infected ...
Cached Medicine News:Health News:Bicycle Helmet Laws For Kids Effective But Not Yet the Norm 2Health News:Bicycle Helmet Laws For Kids Effective But Not Yet the Norm 3Health News:Bicycle Helmet Laws For Kids Effective But Not Yet the Norm 4Health News:Nestlé Recalls Raw Cookie Dough Products 2Health News:Brio Active Brings Whole Body Vibration Fitness to Cherry Hills Village 2Health News:Real-Time Locating Technology Helps Contain Pandemic Outbreaks 2Health News:Real-Time Locating Technology Helps Contain Pandemic Outbreaks 3Health News:Real-Time Locating Technology Helps Contain Pandemic Outbreaks 4
IOL choppers for positioning intraocular lenses. Blunt tip avoids damage to intraocular lenses. For .20mm diameter holes and larger....
...
...
...
Medicine Products: